BioWorld

July 10, 2008

Portola Raises $60M in Series C Extension

Portola Pharmaceuticals Inc. raised $60 million in a Series C extension round to drive its two lead cardiovascular product candidates through Phase II clinical trials. (BioWorld Today) Read More

Study Shows Pipex's Zinc-Based Drug Improved Dry AMD

Drugs, Vaccines, Surveillance for Influenza All Get Boosts

SGX Shares Soar on Merger Giving Lilly Technology Boost

FDA Axing Approvable Letters, Adding Complete Responses

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 5, 2025.

Highridge sells bone healing business to Avista

BioWorld MedTech

In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...